United States

Seattle Genetics Inc (SGEN.O)

SGEN.O on Nasdaq

25 Oct 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint
Monday, 1 Aug 2016 06:59am EDT 

Seattle Genetics Inc : Takeda and Seattle Genetics announce positive data from phase 3 Alcanza clinical trial of ADCETRIS® (Brentuximab Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma . Randomized phase 3 clinical trial with ADCETRIS met primary endpoint . Intend to submit a supplemental biologics license application to FDA in first half of 2017 for approval .Phase 3 trial with ADCETRIS demonstrated highly statistically significant improvement in rate of objective response lasting at least 4 months.  Full Article

Seattle Genetics reports Q2 financial results
Tuesday, 26 Jul 2016 04:02pm EDT 

Seattle Genetics Inc : Sees intiating phase 2 trial of denintuzumab mafodotin (SGN-CD19a; 19A) in frontline diffuse large B-cell lymphoma during 2016. . Seattle Genetics reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S .Q2 revenue $95.4 million versus I/B/E/S view $94.1 million.  Full Article

Seattle Genetics, Inc initiates phase 1/2 trial of vadastuximab talirine
Monday, 22 Feb 2016 08:00am EST 

Seattle Genetics, Inc:Initiates phase 1/2 trial of vadastuximab talirine combination therapy for patients with untreated myelodysplastic syndrome.  Full Article

Seattle Genetics, Inc announces proposed public offering of common stock
Wednesday, 9 Sep 2015 04:01pm EDT 

Seattle Genetics, Inc:Announces proposed public offering of common stock.Says has commenced an underwritten public offering of $400 million of shares of its common stock.Says net proceeds from the offering to fund the ongoing commercialization of adcetris in the United States and Canada.  Full Article

Seattle Genetics initiates clinical trial of adcetris
Thursday, 9 Jul 2015 09:00am EDT 

Seattle Genetics:Says the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus).Lupus is a chronic autoimmune disease in which the body's own immune system overreacts and attacks healthy organs, causing inflammation, pain, permanent organ damage or death.ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on activated lymphocytes that are thought to play a key role in the development of autoimmune diseases, including lupus.Trial is designed to assess the safety and activity of ADCETRIS in adult patients with lupus. ADCETRIS is currently not approved for the treatment of lupus.  Full Article

Seattle Genetics and Unum Therapeutics enter into strategic cancer immunotherapy collaboration
Monday, 8 Jun 2015 09:00am EDT 

Seattle Genetics Inc and Unum Therapeutics:Says two companies have entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer.Under the terms of the agreement, Seattle Genetics will make an upfront payment of $25 mln and an equity investment of $5 mln in Unum's next round of private financing.The companies will initially develop two ACTR products incorporating Seattle Genetics' antibodies, and Seattle Genetics has an option to expand the collaboration to include a third ACTR product.Seattle Genetics and Unum will co-commercialize and share profits 50/50 on any co-developed programs in the United States.Seattle Genetics will retain exclusive commercial rights outside of the United States, paying Unum high single to mid-double digit royalties on ex-U.S. sales.Potential option fee and progress-dependent milestone payments to Unum under the collaboration may total up to $615 million across all three ACTR programs.  Full Article

Seattle Genetics Inc submits supplemental BLA to FDA for phase 3 Aethera trial of Adcetris
Wednesday, 18 Feb 2015 09:00am EST 

Seattle Genetics Inc:Submitted a supplemental Biologics License Application (BLA) to the U.S FDA based on data from the phase 3 AETHERA trial of ADCETRIS as consolidation therapy immediately following an autologous stem cell transplant in Hodgkin lymphoma patients at high risk of relapse.ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL).ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT.  Full Article

BRIEF-Seattle Genetics, Agensys highlights promising Enfortumab Vedotin, ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress

* Seattle Genetics and Agensys, an affiliate of Astellas, highlight promising enfortumab vedotin (ASG-22ME) and ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress Source text for Eikon: Further company coverage: